It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The mosquito-borne Zika virus (ZIKV) belongs to the flavivirus genus of the Flaviviridae family. Contemporary epidemic strains of ZIKV are associated with congenital malformations in infants, including microcephaly, as well as Guillain-Barré syndrome in adults. A risk of human-to-human transmission of ZIKV is also well documented. A worldwide research effort has been undertaken to identify safe and effective strategies to prevent or treat ZIKV infection. We show here that extract from Aphloia theiformis, an edible endemic plant from Indian Ocean islands, exerts a potent antiviral effect against ZIKV strains of African and Asian lineages, including epidemic strains. The antiviral effect of A. theiformis extract was extended to clinical isolates of dengue virus (DENV) of the four serotypes in human hepatocytes. A. theiformis inhibited virus entry in host cells by acting directly on viral particles, thus impairing their attachment to the cell surface. Electron microscopic observations revealed that organization of ZIKV particles was severely affected by A. theiformis. We propose a model of antiviral action for A. theiformis against flaviviruses that highlights the potential of medicinal plants as promising sources of naturally-derived antiviral compounds to prevent ZIKV and DENV infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Gorgette, Olivier 4 ; Gadea, Gilles 1 ; Viranaicken, Wildriss 1 ; Krejbich-Trotot, Pascale 1 ; Mavingui, Patrick 1 ; Desprès, Philippe 1 ; Claudia Nunes Duarte dos Santos 3 ; Guiraud, Pascale 1 ; Jouvenet, Nolwenn 2
; Chaker El Kalamouni 1
1 Université de La Réunion, UM134 Processus Infectieux Insulaire Tropical (PIMIT), INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, Sainte, Clotilde, France
2 UMR CNRS 3569, Viral Genomics and Vaccination Unit, Pasteur Institute, Paris, France
3 Laboratorio de Virologia Molecular, Instituto Carlos Chagas, ICC/FIOCRUZ/PR, Curitiba, Parana, Brazil
4 Ultrastructural BioImaging (UTechsUBI), Pasteur Institute, Paris, France




